1 / 12

Improved Cardiovascular Health with GLP-1 Agonists

Learn about the positive impact of GLP-1 agonists on cardiovascular health, including weight loss, blood pressure, inflammatory markers, and heart failure risk reduction in type 2 diabetics. Discover how GLP-1 agonists help improve cardiovascular outcomes independently of glucose control.

bronald
Download Presentation

Improved Cardiovascular Health with GLP-1 Agonists

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. GLP-1 Agonists and Cardiovascular Health Alan Mathis PharmD Candidate 2013 www.DIABETESINCONTROL.COM Part 2 of 2

  2. Change in Weight by Quartile at 82 Weeks

  3. Change in A1C as a Function of Change in Weight at 82 Weeks

  4. Change in Triglycerides and HDL-C as Function of Weight-Change Quartile at 82 Weeks

  5. Effects of GLP-1 agonists on inflammatory markers • GLP-1 agonists have been shown to reduce several inflammatory markers including plasminogen activa­tor inhibitor-1 (PAI-1), vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) • E-selectin was not significantly reduced • C-reactive protein has also been associated with increased cardiovascular disease • Patients treated with exenatide showed marked decrease in c-reactive protein levels after an 82-week study (from 3.21mg/dL to 1.35 mg/dL) Kendall DM, Bhole D, Guan X, et al.: Exenatide treatment for 82 weeks reduced C-reactive protein, HbAlc, and body weight in patients with type 2 diabetes mellitus. Presented at 42nd Congress of EASD.Copenhagen, Denmark; September 14-17, 2006.

  6. Change in Blood Pressure as Function of Weight-Change Quartile at 82 Weeks

  7. Exenatide Treatment: 3.5-Year Follow-up

  8. Adding Exenatide to Glucose-Lowering regimen reduces heart failure risk • 50,330 patients taking exenatide with insulin and another antidiabetic treatment were 57% less likely to develop heart failure compared to those that took insulin, antidiabetic treatment, but no exenatide (OR 0.43; 95% CI 0.35-0.53) • 53,446 patients who received exenatide and other noninsulin therapies were 31% less likely to develop heart failure compared to those that took a noninsulin therapy and no exenatide (OR 0.69; 95% CI 0.44-1.07) • After combining data, patients who took exenatide were 54% less likely to develop heart failure than those that were not (OR 0.46; 95% CI 0.38-0.56) Best JH, Maggs D, Little W, et al. The risk of heart failure among patients receiving exenatide twice daily versus other glucose-lowering medications for diabetes: a matched retrospective analysis of the GE Healthcare EMR data. Diabetologia 2011; 54(Suppl. 1): S1–S542.

  9. Cardiac Actions of GLP-1 • ↑ Cardiac output, ↓ LV end diastolic pressure, and ↑ myocardial glucose uptake in animal (rodent and dog) models of CHF and myocardial injury • ↓Infarct size in ischemic animal models • ↑ LVEF and ↑ wall motion in humans with MI and EF <40% • GLP-1 (9-36)amide ↑ myocardial contractility (dp/dt) and glucose uptake in dogs with cardiomyopathy

  10. Exenatide and CV outcomes- 430,000 patients-near 40,000 on exenatide Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily orOther Glucose-Lowering Therapies A retrospective analysis of the LifeLink database JENNIE H. BEST, PHD, Diabetes Care 34:90–95, 2011 1

  11. Summary of PharmacologicIncretin Actions on Different Target Tissues Heart Brain Neuroprotection Stomach Appetite Gastric Emptying Cardioprotection Cardiac Output GLP-1 _ Liver GI Tract Insulin Secretion β-Cell Neogenesis β-Cell Apoptosis Glucagon Secretion Glucose Production + Glucose Uptake Muscle Drucker DJ, Cell Metab. 2006;3:153-165.

  12. Summary • GLP-1 agonists not only help reduce plasma glucose levels in type-2 diabetics, but also help improve markers of cardiovascular function including blood pressure, cholesterol, and weight loss. • GLP-1 agonists are shown to have positive effects on cardiovascular outcomes and reduce the risk for heart failure • These benefits to cardiovascular health are independent of GLP-1 agonists’ effect on glucose control and add important cardiocascular effects for type-2 diabetics.

More Related